+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying PRL-02 depot, a potential injectable treatment for men with advanced prostate cancer, including those whose cancer has returned or not responded to previous treatments. The trial aims to evaluate the safety and tolerability of PRL-02 depot alone or combined with enzalutamide, as well as to determine the appropriate dose. This Phase 1 study is sponsored by Astellas Pharma Global Development, Inc. and focuses on men with metastatic or biochemical relapse forms of prostate cancer. Participants will be divided into groups receiving different doses of PRL-02 depot injected into a muscle every 12 weeks. They will also take daily oral doses of either dexamethasone, prednisone, or enzalutamide depending on their study group and prior treatments. The study has two parts dose escalation with small groups receiving increasing doses, and dose expansion involving men previously treated with specific hormone therapies. During the trial, men will visit the clinic multiple times for health checks, scans, and blood tests to monitor side effects, disease progression, and testosterone suppression. After the final visit, those whose cancer has not worsened will continue to have periodic health assessments and scans. The main outcomes include tracking dose limiting toxicities and adverse events over up to four years, along with detailed pharmacokinetic and response measurements.

Age: 18Years +MALEPhase 1
25 locations
R

Actively Recruiting

Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.

Age: 18Years +MALEPhase 3
346 locations
E

Actively Recruiting

Researchers are comparing the disease-free survival in adults with intermediate-risk non-muscle invasive bladder cancer IR-NMIBC who receive either TAR-210 or the investigators choice of intravesical chemotherapy. The study focuses on participants with susceptible FGFR alterations and aims to evaluate the efficacy and safety of these treatments over approximately four years. This is a phase 3 randomized trial sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to one of two groups. Group A receives TAR-210, which is inserted into the bladder on Day 1 and removed after 12 weeks this procedure is repeated every 12 weeks for about one year. Group B receives intravesical chemotherapy with mitomycin C MMC or gemcitabine, chosen by the investigator. Chemotherapy is given once weekly for 4 to 6 doses, followed by a maintenance phase lasting at least 6 months and up to one year. Throughout the study, participants undergo multiple cystoscopies and tissue assessments to monitor for recurrence or progression of bladder cancer. Researchers measure disease-free survival, time to next treatment, recurrence-free survival, progression-free survival, adverse events, overall survival, and quality of life using standardized questionnaires. Safety is monitored from the first dose through 30 days after the last dose. The total participation period spans about four years and two months for comprehensive evaluation.

Age: 18Years +All GendersPhase 3
193 locations
P

Actively Recruiting

Researchers are evaluating the combination of rinzimetostat with darolutamide compared to physicians choice of control treatmentseither androgen receptor pathway inhibitors darolutamide or enzalutamide or docetaxel chemotherapyin patients with metastatic castration resistant prostate cancer mCRPC who have previously been treated with abiraterone acetate. This global, randomized, open-label phase 3 study aims to determine if the combination improves radiographic progression free survival. Participants are assigned to one of two groups the investigational arm receiving rinzimetostat at 400 mg once daily plus darolutamide at 600 mg twice daily, or the control arm receiving physicians choice of either darolutamide, enzalutamide, or docetaxel administered intravenously every 21 days for up to 10 cycles. The study treatment period extends up to approximately two years, with additional long-term follow-up for various outcomes up to five years. During the study, participants undergo regular assessments including imaging scans reviewed centrally to measure disease progression, blood tests for prostate specific antigen PSA levels, and patient-reported questionnaires on pain and quality of life. Researchers monitor overall survival, response rates, side effects, and pharmacokinetics. The study continues safety and efficacy follow-up for several years, with total participation lasting up to around four to five years depending on individual outcomes.

Age: 18Years +MALEPhase 3
15 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of TYRA-300 in adults with FGFR3 altered low grade, intermediate risk non-muscle invasive bladder cancer NMIBC. This phase 2, multicenter, open-label study focuses on patients who have specific genetic alterations in the FGFR3 gene and have a confirmed low-grade NMIBC tumor. The purpose is to better understand how this oral drug works in this specific group of bladder cancer patients. Participants will receive one of three self-administered daily doses of the study drug TYRA-300 as oral tablets 50 mg, 60 mg, or 70 mg. The study is randomized and parallel in design, with all participants receiving the active drug in different dose cohorts. The drug is taken daily and treatment effects will be assessed over time, with follow-up lasting up to 24 months in some cases. During the study, participants will undergo regular assessments to monitor the drugs effects and safety, including evaluations of tumor response and recurrence. Key measures include the rate of complete response at 3 months, overall response rates up to 24 months, and the duration of response. Safety will be monitored through adverse event tracking. Participants will be followed for up to two years to assess longer-term outcomes and any side effects associated with TYRA-300.

Age: 18Years +All GendersPhase 2
48 locations
S

Actively Recruiting

This trial focuses on men with metastatic castrate-resistant prostate cancer mCRPC who have previously been treated with PROVENGE4 immunotherapy. The study aims to investigate changes in immune responses following a booster dose of sipuleucel-T, an immunotherapy treatment. The trial is a phase 2, multicenter, open-label study designed to better understand immune boost responses in this patient group. Participants who have completed their initial treatment with PROVENGE4 will be randomly assigned to one of two groups one group will receive a single booster infusion of sipuleucel-T approximately 6 to 9 months after their initial treatment, while the other group will not receive any additional intervention. The sipuleucel-T is delivered as an intravenous infusion. Both groups will be monitored according to the study schedule. Throughout the study, participants will undergo evaluations to measure immune responses to specific prostate cancer antigens after the booster infusion. Researchers will also monitor adverse events and overall survival over a 5-year period. The study involves regular follow-up visits to assess safety and immune activity, with total participation lasting up to five years after treatment.

Age: 18Years +MALEPhase 2
31 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Cretostimogene Grenadenorepvec in people with high-risk non-muscle-invasive bladder cancer NMIBC. This Phase 2, multi-arm, open-label study includes participants who are either new to Bacillus Calmette-Guerin BCG treatment, previously treated with BCG, or unresponsive to BCG. The study aims to compare different administration methods and combinations with gemcitabine to better understand treatment options for this condition. Participants are divided into several groups based on their disease status and prior BCG treatment. The study drug Cretostimogene is administered directly into the bladder weekly for six weeks as an induction course, followed by reinduction for certain participants. Maintenance treatment involves cycles of three weekly doses every three months in the first year and every six months in the second year, with an optional extension to the third year. Some groups receive Cretostimogene alone, while others receive it combined with gemcitabine through alternative instillation methods. Participants will have their disease status monitored through urine tests, bladder visualizations like cystoscopy, upper urinary tract assessments, and biopsies if needed every three months for two years, then every six months for up to an additional two years or until disease recurrence. The study measures include complete response rates, event-free survival, and safety outcomes over periods ranging from weeks to 48 months. Overall participation may last several years, with careful follow-up to assess treatment impact and safety.

Age: 18Years +All GendersPhase 2
80 locations
E

Actively Recruiting

Researchers are evaluating Dabogratinib TYRA-300 in a Phase 2AB study involving participants with Low Grade Upper Tract Urothelial Carcinoma LG UTUC. This open-label, multi-center trial aims to assess the safety and effectiveness of Dabogratinib in treating this specific type of urothelial carcinoma, focusing on participants with FGFR3 positive tumors. The study is sponsored by Tyra Biosciences, Inc and includes randomized treatment groups receiving different doses of Dabogratinib. Participants receive Dabogratinib as a self-administered oral tablet daily at either 60mg or 80mg doses. The study includes two treatment cohorts and is designed to monitor the drugs impact on tumor response, including complete response rates and duration of response. The trial allows evaluation over a period of up to 36 months for response duration and up to 2 years for safety, renal preservation, and tumor resectability changes. During the trial, participants undergo assessments to measure tumor response, safety, and tolerability. Marker lesions are identified prior to randomization and monitored throughout. Researchers track outcomes including complete response rates within 6 months, maintenance of response at 12 and 24 months, and kidney function preservation. Laboratory tests, imaging, and clinical evaluations are performed regularly. The total participation time can extend up to several years to capture long-term effects and safety data.

Age: 18Years +All GendersPhase 2
36 locations
P

Actively Recruiting

Researchers are evaluating ORIC-944, a selective small molecule inhibitor targeting PRC2, in patients with metastatic prostate cancer. This open-label, phase 11b study aims to establish the safety and preliminary antitumor activity of ORIC-944 both alone and combined with androgen receptor pathway inhibitors ARPIs. The study involves patients who have progressed after prior ARPI therapies and explores dose escalation and optimization across different patient groups. Participants receive ORIC-944 orally once daily in 28-day continuous cycles either alone or combined with ARPIs such as abiraterone, apalutamide, darolutamide, or enzalutamide. The study has three parts Part I tests ORIC-944 alone Part II tests combinations with ARPIs Part III optimizes dosing of ORIC-944 with ARPIs in separate cohorts. Future combinations with abiraterone or enzalutamide may also be explored. During the study, participants undergo assessments including skin and tumor biopsies and monitoring of organ function and performance status. Researchers measure drug concentrations in the blood, antitumor responses, progression-free survival, and PSA levels. Safety and activity are evaluated over months, with follow-up for up to 36 months. The trial is sponsored by ORIC Pharmaceuticals and runs from 2022 to 2028.

Age: 18Years +MALEPhase 1
27 locations

1-10 of 12

1